BerandaAMRN • NASDAQ
add
Amarin Corporation PLC
Tutup sebelumnya
$14,12
Rentang hari
$13,78 - $14,07
Rentang tahun
$7,08 - $20,90
Kapitalisasi pasar
285,72Â jt USD
Volume Rata-Rata
91,39Â rb
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 49,22Â jt | -21,00% |
Biaya operasional | 25,43Â jt | -40,80% |
Penghasilan bersih | -1,22Â jt | 97,48% |
Margin laba bersih | -2,49 | 96,81% |
Penghasilan per saham | 0,01 | 102,50% |
EBITDA | -1,39Â jt | 90,90% |
Tarif pajak efektif | -43,66% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 302,59Â jt | 2,84% |
Total aset | 670,78Â jt | -2,13% |
Total liabilitas | 211,49Â jt | 6,19% |
Total ekuitas | 459,28 jt | — |
Saham yang beredar | 20,81 jt | — |
Harga terhadap nilai buku | 0,64 | — |
Tingkat pengembalian aset | -0,85% | — |
Tingkat pengembalian modal | -1,21% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -1,22Â jt | 97,48% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
Didirikan
1 Mar 1989
Kantor pusat
Situs
Karyawan
275
